Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsAssaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.
Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.
Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.
The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.
Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.
Doug Kerr, MD, PhD, chief medical officer at Dyne Therapeutics, discusses the clinical development of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy.
This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.
1.
Study finds 1 in 12 patients labeled as having 'benign' results actually had high-risk prostate cancer
2.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
3.
An effective treatment for a rare but deadly form of cancer
4.
24 months after radical prostateectomy, no PSA recurrence was observed when using apalutamide plus ADT.
5.
Does diabetes impact the prognosis of people with colorectal cancer?
1.
Beyond the Biopsy: The Evolving Landscape of Prostate Cancer Management
2.
A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease
3.
Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern
4.
What You Need to Know About the Early Warning Signs of Colon Cancer
5.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
3.
Navigating the Complexities of Ph Negative ALL - Part X
4.
Navigating the Complexities of Ph Negative ALL - Part XVI
5.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge